Publicaciones Google Scholar de
1980 a
2022
| Título |
Fuente |
Fecha |
| TDP-43 modulation by tau-tubulin kinase 1 inhibitors: A new avenue for future amyotrophic lateral sclerosis therapy |
Journal of Medicinal Chemistry 65 (2), 1585-1607 , 2022 |
2022 |
| Retinal neurodegeneration and neuroinflammation in a SOD1 mouse model of ALS |
Acta Ophthalmologica 100 , 2022 |
2022 |
| BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis |
International Journal of Molecular Sciences 22 (22), 12533 , 2021 |
2021 |
| Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis |
Molecules 26 (24), 7643 , 2021 |
2021 |
| Use of cannabinoids in the treatment of a neurodegenerative disease or disorder |
US Patent App. 16/629,722 , 2021 |
2021 |
| Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis |
British Journal of Pharmacology 178 (6), 1253-1256 , 2021 |
2021 |
| Targeting the CB 2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis |
British journal of pharmacology 178 (6), 1373-1387 , 2021 |
2021 |
| Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis |
European Journal of Medicinal Chemistry 210, 112968 , 2021 |
2021 |
| Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis |
Brain Pathology 31 (6), e12972 , 2021 |
2021 |
| Retinal microglial activation in a SOD1 mouse model of ALS |
Acta Ophthalmologica 99 , 2021 |
2021 |
| Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis |
International Journal of Molecular Sciences 22 (4), 1663 , 2021 |
2021 |
| Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis (vol 178, pg 1253, 2021) |
BRITISH JOURNAL OF PHARMACOLOGY 178 (10), 2162-2162 , 2021 |
2021 |
| Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis |
International Journal of Molecular Sciences 22 (16), 8975 , 2021 |
2021 |
| Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders |
Biomolecules 10 (2), 279 , 2020 |
2020 |
| Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System |
New Tools to Interrogate Endocannabinoid Signalling, 10-47 , 2020 |
2020 |
| Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment |
Scientific Reports 10 (1), 1-12 , 2020 |
2020 |
| Characterisation of a new model of frontotemporal dementia for neuroprotective studies with cannabinoids |
EUROPEAN NEUROPSYCHOPHARMACOLOGY 29, S664-S665 , 2019 |
2019 |
| Targeting glial cannabinoid CB 2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic … |
British journal of pharmacology 176 (10), 1585-1600 , 2019 |
2019 |
| Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients |
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19 (5-6), 377-386 , 2018 |
2018 |
| Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis |
Biochemical pharmacology 157, 217-226 , 2018 |
2018 |
| Aumentando la presencia de la UCM en los MOOCs: Puesta en marcha de un curso online sobre neurociencia |
|
2017 |
| Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis |
Disease models & mechanisms 10 (5), 551-558 , 2017 |
2017 |
| Endocannabinoids and amyotrophic lateral sclerosis |
Cannabinoids in Neurologic and Mental Disease, 99-123 , 2015 |
2015 |
| The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9 … |
Multiple sclerosis and related disorders 4 (6), 505-511 , 2015 |
2015 |
| A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis |
British journal of pharmacology 172 (14), 3579-3595 , 2015 |
2015 |
| Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders |
Journal of Neuroimmune Pharmacology 10 (2), 233-244 , 2015 |
2015 |
| Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1 G93A Transgenic Mice and Evaluation of a Sativex ® ‐like Combination of … |
CNS neuroscience & therapeutics 20 (9), 809-815 , 2014 |
2014 |
| 026 Química. Investigaciones en fármacos cannabinoides para las enfermedades neurológicas |
La uni en la calle: Libro de textos., 68-69 , 2013 |
2013 |
| Experiencia sobre la evaluación continúa a través del Campus Virtual |
Valorar, validar y difundir Campus Virtual, 207-210 , 2013 |
2013 |
| Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases |
Neuroscience letters 508 (2), 67-72 , 2012 |
2012 |
| Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects |
Neuropharmacology 62 (7), 2299-2308 , 2012 |
2012 |
| The endocannabinoid system as a target for the treatment of neuronal damage |
Expert opinion on therapeutic targets 14 (4), 387-404 , 2010 |
2010 |
| Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain |
European Journal of Neuroscience 31 (8), 1414-1422 , 2010 |
2010 |
| Cannabinoids, multiple sclerosis and neuroprotection |
Expert review of clinical pharmacology 2 (6), 645-660 , 2009 |
2009 |
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties |
Brain research 1134, 162-170 , 2007 |
2007 |
| Cannabinoids and neuroprotection in basal ganglia disorders |
Molecular neurobiology 36 (1), 82-91 , 2007 |
2007 |
| Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions |
Life sciences 80 (10), 979-988 , 2007 |
2007 |
| Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1‐mediated calcium responses in adult DRG neurons; the role of CB1 receptors |
European Journal of Neuroscience 24 (12), 3489-3495 , 2006 |
2006 |
| Number 1—January 2006 |
European Neuropsychopharmacology 16, 643-648 , 2006 |
2006 |
| Acyl‐based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations |
Journal of neurochemistry 99 (2), 677-688 , 2006 |
2006 |
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the … |
European neuropsychopharmacology 16 (1), 7-18 , 2006 |
2006 |
| Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels |
Biochemical pharmacology 70 (3), 446-452 , 2005 |
2005 |
| Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis |
Neurobiology of disease 20 (2), 207-217 , 2005 |
2005 |
| Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease |
Brain research 1050 (1-2), 210-216 , 2005 |
2005 |
| Involvement of the endocannabinoid system in motor disorders |
Current Medicinal Chemistry-Central Nervous System Agents 4 (3), 175-182 , 2004 |
2004 |
| In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake |
European journal of pharmacology 484 (2-3), 249-257 , 2004 |
2004 |
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence |
Brain research 1007 (1-2), 152-159 , 2004 |
2004 |
| Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors |
European journal of medicinal chemistry 38 (4), 403-412 , 2003 |
2003 |
| Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase |
Journal of medicinal chemistry 46 (8), 1512-1522 , 2003 |
2003 |
| UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide |
European journal of pharmacology 449 (1-2), 99-103 , 2002 |
2002 |
